InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “GMP Biologics Market”-, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031.”
The GMP Biologics Market is estimated to reach over USD 153.9 Bn by 2031, exhibiting a CAGR of 14.6% during the forecast period.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2715
Good Manufacturing Practices (GMP) represent a rigorous set of regulatory standards and operational protocols designed to ensure the safety, quality, and integrity of pharmaceutical and biological products throughout the manufacturing process. Biologic therapies, which are derived from living cells or organisms, exert their therapeutic effects by interacting with human metabolic systems to modulate or enhance physiological functions.
These include hormone-based treatments for endocrine disorders and vaccines that activate immune responses. Strict adherence to GMP is critical in biologics manufacturing, as it minimizes the risk of contamination, mitigates manufacturing errors, and ensures the stability and efficacy of products across their lifecycle.
Biologics are inherently more complex than traditional small-molecule drugs due to their biological origin. This complexity introduces variability influenced by environmental conditions, genetic diversity, disease exposure, and potential biological contaminants. As a result, the manufacturing of biologic products requires highly controlled processes and stringent GMP compliance to maintain product consistency, safety, and therapeutic effectiveness.
The growing pipeline of approved biologic therapies, along with the expansion of clinical research in this area, is driving increased demand for GMP-compliant manufacturing infrastructure. This trend is particularly pronounced in emerging markets, where improvements in healthcare infrastructure and rising demand for advanced treatments are creating substantial growth opportunities.
To capitalize on this potential, industry stakeholders are expanding their presence in these regions through strategic partnerships and facility development. Simultaneously, advancements in bioprocessing technologies are enhancing manufacturing efficiency and cost-effectiveness, further supporting the global expansion of biologics production and reinforcing GMP’s critical role in ensuring high-quality therapeutic outcomes.
List of Prominent Players in the GMP Biologics Market:
- Amgen Inc.
- Hoffmann-La Roche Ltd
- AbbVie Inc.
- AstraZeneca plc
- Merck KGaA
- Creative Diagnostics
- Fisher Bioservices (Thermo Fisher Scientific)
- Polpharma Biologics
- Intertek
- HemaCare
- AGC
- AstraZeneca plc
- Merck KGaA
- Sanofi
- GlaxoSmithKline plc
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
- Samsung Biologics Co. Ltd.
- WuXi AppTec
- Lonza Group Ltd.
- Rentschler Biopharma SE
- Boehringer Ingelheim International GmbH
- Celltrion Inc
- Catalent Inc.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03
Market Dynamics
Drivers:
The growth of the GMP biologics market is primarily driven by the rising global demand for biopharmaceutical products, including therapeutic proteins, monoclonal antibodies, and vaccines. These biologics offer targeted and efficacious treatment options for a wide array of chronic and complex medical conditions, thereby necessitating robust and compliant manufacturing practices.
The increasing prevalence of diseases such as cancer, autoimmune disorders, and infectious conditions further underscores the need for high-quality biologic therapies. To ensure safety, efficacy, and regulatory compliance, manufacturers are required to adhere to stringent GMP standards.
Additionally, biopharmaceutical companies are expanding their global manufacturing footprint by establishing GMP-compliant production facilities in strategic international markets. This expansion supports the ability to meet diverse regulatory requirements across regions and improves global patient access to advanced biologic therapies.
Challenges:
Maintaining aseptic conditions throughout the biologics manufacturing process is essential for preserving product quality and ensuring patient safety. Given the biological origin and complexity of these products, the risk of contamination is significantly higher compared to conventional pharmaceuticals. This necessitates continuous process monitoring, rigorous environmental controls, and strict adherence to GMP protocols, all of which contribute to operational complexity and elevated production costs.
Regional Trends:
North America is expected to retain its dominant position in the GMP biologics market over the forecast period. This is attributed to the presence of leading biopharmaceutical firms, advanced technological infrastructure, and well-established regulatory oversight, particularly by agencies such as the U.S. Food and Drug Administration (FDA). The United States remains a global hub for innovation and investment in biologic therapies, including monoclonal antibodies, cell therapies, and gene-based treatments.
In contrast, the Asia-Pacific region is experiencing accelerated growth due to increasing healthcare demand, rising investments in biotechnology, and the development of regional expertise in biologics manufacturing. Countries such as China, India, and South Korea are emerging as significant players, bolstered by supportive government initiatives and expanding biomanufacturing capabilities.
Recent Developments:
- In Feb 2024, Abbie established a strategic relationship with Tentarix Biotherapeutics to explore and create novel, multi-specific, conditionally active biologic candidates in immunology and oncology.
- In June 2023, Wuxi Biologics, which provides comprehensive solutions for biologics R&D and manufacturing, has declared that it can now produce more therapeutic components and pharmaceuticals at its plant in Wuppertal, Germany.
- In March 2023, Samsung Biologic, Incheon, South Korea’s Samsung Biologics is undergoing planned expansion in response to increasing market demand. When the facility is completed, it is expected to have a manufacturing capacity of 180,000 L. The firm plans to invest KRW 1.9 trillion to boost the site’s capacity to 784,000 L.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2715
Segmentation of GMP Biologics Market.
Global GMP Biologics Market- By Type
- Monoclonal Antibodies
- Polyclonal Antibody
Global GMP Biologics Market – By Application
- Hospitals
- Clinics
- Others
Global GMP Biologics Market – By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
